CorMedix Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from CorMedix Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 31.8 times. Higher than 98% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 120.8 times by its yearly operating cash. Higher than 98% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $58 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $3,367 from others' credit three years earlier. More money tied up than 95% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$87Over the last 3 years, every $100 of reported profit came with $87 of operating cash.
Lower than 88% of Healthcare companies in United States.
Self-Funding Ratio
31.8×Over the last 3 years its own operating cash covered its investment spending (capex) 31.8 times.
Higher than 98% of Healthcare companies in United States.
Cash Locked Ratio
$58For every $100 of sales, $58 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $3,367 from others' credit three years earlier.
More money tied up than 95% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$62Sales grew 476,461% in 3 years; of every extra $100 of sales, $62 became extra profit.
Higher than 74% of Healthcare companies in United States.
Asset Productivity Ratio
+476461% / +1232%In 3 years sales changed by +476461% while total assets changed by +1232%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
120.8×Debt due within a year is covered 120.8 times by its yearly operating cash.
Higher than 98% of Healthcare companies in United States.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Lower than 67% of Healthcare companies in United States.
Tangible Assets Ratio
50%Of every $100 the company owns, $50 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 74% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
CorMedix Inc. owes $0.49 for every $1 it owns. CorMedix Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
4.0Investors pay $4.0 for every $1 of CorMedix Inc.'s yearly profit, lower than 87% of Healthcare companies in United States.
P/B ratio
1.37The share price is 1.37 times CorMedix Inc.'s book value per share, lower than 71% of Healthcare companies in United States.
Market cap
$631 MThe total market value of all of CorMedix Inc.'s shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$461 MWhat CorMedix Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.91Net worth divided by the number of shares. The share price of $8.10 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
54.9%CorMedix Inc. earned 54.9% on its shareholders' money over the last year, higher than 97% of Healthcare companies in United States.
Owes vs Owns
0.49×CorMedix Inc. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Dividend yield
NoneCorMedix Inc. does not currently pay a dividend.
Revenue growth
+617%Revenue rose 617% in the year to Dec 2025, and grew 1583% a year on average over 3 years.
Profit growth
Back to profitCorMedix Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
52.3%CorMedix Inc. keeps $52 of every $100 of revenue as net profit.
Cash quality
1.07×Cash from CorMedix Inc.'s business was 1.07× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
54.0×CorMedix Inc.'s operating profit covered its interest costs 54.0 times in the year to Dec 2025.
Cash vs debt
Net debtCorMedix Inc. had $0 M more debt than cash (net debt) at Dec 2025.
Questions
What is CorMedix Inc.'s P/E ratio?
Investors pay $4.0 for every $1 of CorMedix Inc.'s yearly profit, lower than 87% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For CorMedix Inc.: $631 M ÷ $461 M (30 Jun 2026) = 1.4.
What is CorMedix Inc.'s return on equity?
CorMedix Inc. earned 54.9% on its shareholders' money over the last year, higher than 97% of Healthcare companies in United States.
How much does CorMedix Inc. owe compared with what it owns?
CorMedix Inc. owes $0.49 for every $1 it owns (low), higher than 55% of Healthcare companies in United States.
Does CorMedix Inc. pay a dividend?
No. CorMedix Inc. does not currently pay a dividend.
Is CorMedix Inc.'s revenue growing?
Revenue rose 617% in the year to Dec 2025, and grew 1583% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.